Latest News for GRI
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market
Access the “What This Means” segment here
– Live video webcast on Wednesday, February 11 th at 1:00 PM EST
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026
Immuneering (NASDAQ: IMRX - Get Free Report) and GRI Bio (NASDAQ: GRI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Profitability This table compares Immuneering and GRI Bio's
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GRI.
U.S. House Trading
No House trades found for GRI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.